Stock Price Forecast

Dec. 8, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Alkermes plc chart...

About the Company

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.

CEO

Richard F. Pops

Exchange

NASDAQ

Website

www.alkermes.com

$1B

Total Revenue

2K

Employees

$4B

Market Capitalization

-16.80

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ALKS News

How Alkermes (ALKS) Stock Stands Out in a Strong Industry

15d ago, source: Nasdaq

One stock that might be an intriguing choice for investors right now is Alkermes plc ALKS. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings ...

Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference

8d ago, source: Yahoo

DUBLIN, Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap ...

Take A Look At This Alkermes plc (NASDAQ: ALKS) Analysis Before Investing

10d ago, source:

Alkermes plc (NASDAQ:ALKS) price closed lower on Friday, November 25, dropping -0.29% below its previous close. A look at the daily price movement shows that the last close reads $24.27, with intraday ...

Alkermes PLC

24d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference

16d ago, source: Nasdaq

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary ...

Alkermes plc: Alkermes to Participate in the Stifel Healthcare Conference

1mon ago, source: Finanznachrichten

DUBLIN, Nov. 8, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday ...

Alkermes plc

9d ago, source: U.S. News & World Report

High inflation makes dividend stocks more attractive.

Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference

8d ago, source: Benzinga.com

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary ...

Alkermes to Participate in the 5th Annual Evercore ISI HealthCONx Conference

16d ago, source: Yahoo Finance

DUBLIN, Nov. 22, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on ...

Alkermes plc: Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference

8d ago, source: Finanznachrichten

DUBLIN, Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap ...

Alkermes To Participate In The Bofa Securities 2022 Biotech SMID Cap Conference'

8d ago, source:

PRNewswire/ -- alkermes plc (Nasdaq: alks ) announced today that management will participate in a fireside chat as part of ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...